Aarti Drugs Limited — Updates, 06-05-2025: Press Release

Aarti Drugs has announced a board meeting to discuss the financial results for the quarter and half-year. Q4 revenue rose 9% YoY to Rs. 679 Cr, supported by robust API exports, with a 14% EBITDA margin and 33% PAT growth. FY25 revenue fell 5% YoY to Rs. 2,403 Cr amid soft global demand and input cost volatility; margins remained stable at 12.6%. The company resumed US exports after FDA cleared its Tarapur API facility and advanced its solar power collaboration. Greenfield projects at Sayakha and Tarapur continue on track.